Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Murrell

Showing results (441-450 of 491) with videos related to

Pageof 50
Sort By:
JAMA Dermatology|August 9, 2013
Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaireDeshan F Sebaratnam, Anna Marie Hanna, Shien-ning Chee, et al.
BMC Cancer|April 20, 2019
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Journal of Drugs in Dermatology : JDD|June 5, 2023
Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled TrialJoyce Teng, Amy S. Paller, Anna L. Bruckner, et al.
BMC Cancer|May 18, 2017
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
The British Journal of Dermatology|May 4, 2021
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE studyD F Murrell, A Patsatsi, P Stavropoulos, et al.
The British Journal of Dermatology|August 17, 2022
A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradationMathilde C S C Vermeer, Mohammad Al-Shinnag, Herman H W Silljé, et al.
Trends in Cancer|March 13, 2025
Leveraging space innovations for cancer breakthroughs on EarthHossein Akbarialiabad, Parnian Jamshidi, Zahra Aminzade, et al.
Cancer Research|May 9, 2012
Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosaYi-Zhen Ng, Celine Pourreyron, Julio C Salas-Alanis, et al.
International Journal of Dermatology|January 13, 2010
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studiesPeter Foley, Michael Freeman, Alan Menter, et al.
Journal of the American Academy of Dermatology|January 1, 2017
Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseasesNina van Beek, Cornelia Dähnrich, Nora Johannsen, et al.
Pageof 50

Showing results (441-450 of 491) with videos related to

Sort By:
Pageof 50
JAMA Dermatology|August 9, 2013
Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaireDeshan F Sebaratnam, Anna Marie Hanna, Shien-ning Chee, et al.
BMC Cancer|April 20, 2019
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Journal of Drugs in Dermatology : JDD|June 5, 2023
Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled TrialJoyce Teng, Amy S. Paller, Anna L. Bruckner, et al.
BMC Cancer|May 18, 2017
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
The British Journal of Dermatology|May 4, 2021
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE studyD F Murrell, A Patsatsi, P Stavropoulos, et al.
The British Journal of Dermatology|August 17, 2022
A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradationMathilde C S C Vermeer, Mohammad Al-Shinnag, Herman H W Silljé, et al.
Trends in Cancer|March 13, 2025
Leveraging space innovations for cancer breakthroughs on EarthHossein Akbarialiabad, Parnian Jamshidi, Zahra Aminzade, et al.
Cancer Research|May 9, 2012
Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosaYi-Zhen Ng, Celine Pourreyron, Julio C Salas-Alanis, et al.
International Journal of Dermatology|January 13, 2010
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studiesPeter Foley, Michael Freeman, Alan Menter, et al.
Journal of the American Academy of Dermatology|January 1, 2017
Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseasesNina van Beek, Cornelia Dähnrich, Nora Johannsen, et al.
Pageof 50